PubMed · 8691491
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
R J Anderson, K Alonso. 1996. The ALLHAT challenges.. https://pubmed.ncbi.nlm.nih.gov/8691491/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The action of carvedilol, a vasodilating, beta-adrenoceptor blocking agent, against lipid peroxidation has been the subject of many studies, but the results reported thus far are contradictory. In an attempt to define the antioxidant mechanism of carvedilol against lipid peroxidation, the dynamics of the action of carvedilol were studied in several oxidation systems. We investigated the reactivity of carvedilol toward radicals and its inhibitory effect on lipid peroxidation induced by several kinds of initiating species such as azo compounds and metal ions in solution, micelles, membranes, and low-density lipoprotein. Carvedilol exerted poor reactivity toward phenoxyl, alkoxyl, and peroxyl radicals in acetonitrile solution nor did it show an appreciable antioxidant effect against either the peroxyl radical-induced oxidation of methyl linoleate in acetonitrile or against phosphatidylcholine liposomal membranes in aqueous suspension. Carvedilol completely inhibited the ferric ion-induced oxidation of methyl linoleate micelles by sequestering ferric ions, but not by reducing hydroperoxide. It was shown that carvedilol enhanced the oxidation of micelles induced by either methemoglobin or peroxyl radical. Carvedilol, which was added exogenously, did not suppress the oxidation of isolated low-density lipoprotein induced by peroxyl radical or cupric ion. These results show that carvedilol does not act as a radical-scavenging antioxidant, but that it does act most efficiently as an antioxidant against ferric ion-induced oxidation by sequestering ferric ion.
Data from a controlled clinical trial in liver cirrhosis are used to illustrate that multi-state models may be a useful tool in the analysis of data where survival is the ultimate outcome of interest but where intermediate, transient states are identified. We compare models for the marginal survival time distribution with models including transient states, both with respect to their clinical interpretation and with respect to the precision of survival probability estimates obtained from the various models.
Tre treatment of hypertension in type 2 diabetes in currently much in focus. The aim of this treatment is to prevent cardiovascular disease by reducing the mean blood pressure level to less than 140/85 mm Hg in all patients who do not experience orthostatic reactions. In most patients it seems as if the strict blood pressure control is more important for the prognosis than the choice made of specific drug therapy. Nevertheless, specific pharmacological properties may be of special importance for some patients. During the last few years several new randomised trials have increased our knowledge for an approach based on evidence-based medicine towards hypertension in type 2 diabetes. These studies are summarized and discussed in this paper. Of particular importance is that normally a combination-therapy is needed in the vast majority of patients. Synergistic drugs should therefore be combined to achieve an optimal blood pressure control with a minimum of side effects.